Wang Ling, the deputy director of the Provincial Drug Administration, recently led a team to Shenzhen for a discussion and exchange with representatives of the National People’s Congress and members of the Chinese People’s Political Consultative Conference (CPPCC). The purpose of the meeting was to gain a deeper understanding of the proposals and suggestions put forward by the deputies and strengthen communication to ensure effective replies.
On June 9, Wang Ling met with Deng Qinghe, a member of the National Committee of the CPPCC, and representatives of the Provincial People’s Congress in Shenzhen. During the meeting, Liu Xiang and Sun Yong, members of the Provincial Political Consultative Conference, presented their proposal ideas. Liu Xiang proposed supporting the expansion of the pilot project “Hong Kong and Macau Drug Device Link” in Shenzhen to a “Global Drug Device Link.” He also suggested that the policy of “Hong Kong and Macau Drug Device Link” should include international new drugs as a new direction of development. Sun Yong introduced a proposal to relax the registration and sales of Chinese patent medicines for internal use registered in Hong Kong and Macau in the Greater Bay Area. He also recommended further research on simplifying the approval procedures for Chinese patent medicines for internal use registered in Hong Kong and Macau in mainland China.
In response to these proposals, Wang Ling expressed a positive attitude towards expanding the “Hong Kong-Macau Medicine-Device Link” to a “Global Medicine-Device Link.” He emphasized the need for strict control of entry barriers through “double designation” and the introduction of supporting policies and systems. These measures aim to ensure the effective implementation of policies and enhance the well-being and security of residents in the Guangdong-Hong Kong-Macao Greater Bay Area and the entire country. Wang Ling also highlighted the latest achievements in the registration and listing of Hong Kong and Macao proprietary Chinese medicines for external use in mainland China. He emphasized the ongoing efforts to optimize the approval process, provide more convenience for Hong Kong and Macao enterprises, and assist high-quality Hong Kong and Macao traditional Chinese patent medicines in registering for listing in mainland China.
The symposium was characterized by a lively atmosphere, and the topics were thoroughly discussed. Representatives from the Administrative Licensing Office of the Provincial Drug Administration and the Shenzhen Market Administration also participated in the discussion.
This news article highlights the efforts of Wang Ling and his team to engage with representatives of the National People’s Congress and CPPCC members in Shenzhen. The exchange of ideas and proposals aims to improve drug administration policies and enhance the development of the healthcare industry in the Guangdong-Hong Kong-Macao Greater Bay Area.
How can the supervision and management of online drug sales platforms be strengthened in Shenzhen?
O strengthen the supervision and management of online drug sales platforms in Shenzhen.
Wang Ling expressed his appreciation for the valuable proposals and suggestions put forward by the representatives. He emphasized the importance of further promoting the development of the pharmaceutical industry and ensuring drug safety and efficacy. He also emphasized the need to strengthen the supervision and regulation of online drug sales platforms to protect the health and safety of the public.
During the discussion, Wang Ling shared the progress made by the Provincial Drug Administration in implementing drug safety measures and measures to combat illegal drug activities. He also emphasized the importance of collaboration between different government departments and agencies to ensure the effective implementation of policies and regulations.
Deng Qinghe praised the efforts of the Provincial Drug Administration in maintaining drug safety and expressed his support for the proposals and suggestions put forward by Liu Xiang and Sun Yong. He also highlighted the importance of international collaboration in drug regulation and the importance of incorporating international new drugs into the “Hong Kong and Macau Drug Device Link” policy.
The meeting concluded with a discussion on further cooperation and coordination between the Provincial Drug Administration, the National People’s Congress, and the CPPCC to address the challenges and opportunities in the pharmaceutical industry. Wang Ling emphasized the need for continuous communication and exchange of ideas to ensure the effective implementation of policies and regulations related to the pharmaceutical industry.
Overall, the meeting served as a platform for valuable discussions and exchange of ideas between the Provincial Drug Administration and representatives of the National People’s Congress and CPPCC. It highlighted the importance of collaboration and communication in addressing the challenges and opportunities in the pharmaceutical industry and ensuring drug safety and efficacy.
